BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines total Research & Development Expense ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations & MD&A
Latest, Q2 2026
612
Period ended Jun 30, 2026
Change on a year earlier
+16.7%
525 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
34
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Research & Development Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 612 | +16.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 541 | +12.3% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 615 | +13.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 524 | +5.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 525 | +15.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 482 | +4.6% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 542 | +9.7% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 496 | +9.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 455 | +7.5% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 461 | +12.7% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 494 | +10.8% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 453 | +6.3% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 423 | +11.8% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 409 | +4.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 446 | +3.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 426 | +21.2% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 378 | +6.2% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 390 | +21.6% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 431 | +21.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 352 | +0.8% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 356 | +24.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 321 | +5.4% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 356 | +25.5% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2020 | Sep 30, 2020 | 349 | +47.3% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 286 | +25.0% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 304 | +70.7% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 283 | +10.0% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 237 | +60.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 229 | +39.3% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 178 | +62.5% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 258 | +182.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 148 | +68.3% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 164 | +247.9% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 110 | +156.3% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 91.3 | +215.9% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 87.7 | +191.4% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2017 | Jun 30, 2017 | 47.2 | +123.7% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 42.8 | +139.1% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2016 | Dec 31, 2016 | 28.9 | +2.8% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2016 | Sep 30, 2016 | 30.1 | +126.3% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 21.1 | +214.9% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 17.9 | +77.2% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 28.1 | – | Form 10-K (filed 2018-02-28) ↗ |
| Q3 2015 | Sep 30, 2015 | 13.3 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 6.70 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 10.1 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up total research & development expense ($m)
Cite this data
StockData. (2026). BeOne Medicines Total Research & Development Expense ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.